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This study compared the results of tumour necrosis factor alpha (TNF-α), interleukin-2 soluble receptor (sIL-2R), nitric ox-
ide metabolites (NOx), C-reactive protein (CRP), and lipids (total cholesterol, high-density lipoprotein (HDL-cholesterol), low-
density lipoprotein (LDL-cholesterol), and triglycerides) between control group (nondiabetic subjects) and overweight type 2
DM subjects. To restrict the inﬂuence of variables that could interfere in the interpretation of data, subjects with obesity and/or
acute or chronic inﬂammatory disease, haemoglobinopathies, recent use of antibiotics, antiinﬂammatory drugs, and trauma were
excluded. Type 2 DM patients (n = 39; age 53.3 ± 9.0 years; median glycated haemoglobin A1c < 8%) presented higher levels of
TNF-α,triglycerides(P<. 01),NOx andsIL-2R(P<. 05)thancontrolgroup(n = 28;age39.7±14.1years).CRP,LDL-cholesterol,
total cholesterol, and HDL-cholesterol did not diﬀer among groups. Diabetic women (n = 21) had higher levels of TNF-α,t o t a l
cholesterol, LDL-cholesterol, and HDL-cholesterol than diabetic men (n = 18) (P<. 0 5 ) ,b u tt h e r ew e r en od i ﬀerences among
sexes in the control group. This study indicates that increased level of proinﬂammatory markers occurs in type 2 DM even in the
absence of obesity and marked hyperglycaemia, conﬁrming that the inﬂammation course of the atherosclerotic process is more
severe in diabetic patients than in nondiabetic subjects.
Copyright © 2006 Fl´ avia Ozorio Pereira et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Type 2 diabetes mellitus (DM) is associated with an athero-
genic status that is related to the presence of a vascular low-
grade inﬂammation. However, the presence of other risk fac-
tors, besides diabetes, limits the analysis of the diabetic state
per se in the development of the macrovascular complica-
tions. According to the United Kingdom Prospective Dia-
betes Study (UKPDS) Group [1], the cardiovascular risk in
this group is signiﬁcantly increased when smoking, obesity,
hypertension, and dyslipidemia are present. Since type 2 DM
has both elevated morbidity and mortality ratios, it is now
classiﬁed within the high-risk category for developing a car-
diovascular event in a similar manner as a nondiabetic per-
son with an established macrovascular complication [2].
Considering that inﬂammatory markers such as cy-
tokines and C-reactive protein (CRP), besides lipid levels,
may be raised several years before a major cardiovascular
event, the aim of this study was to evaluate the serum levels
of tumour necrosis factor (TNF-α), the soluble interleukin-2
receptor (sIL-2R), nitric oxide metabolites (NOx), CRP, and
lipids (total cholesterol, high-density lipoprotein (HDL-
cholesterol), low-density lipoprotein (LDL-cholesterol),
and triglycerides) among type 2 diabetic and nondiabetic
subjects. Since it is well known that type 2 DM subjects have
multiple risk factors that potentiate each other, we limit our
study to diabetic individuals with body mass index (BMI)
less than 30 and glycated haemoglobin (HbA1c)b e l l o w8 %
[3].
SUBJECTS AND METHODS
Subjects
The studied groups included 40 outpatients with type 2 DM
(18 males and 22 females; ages (mean±SD) 54.2±9.2years)2 Mediators of Inﬂammation
and 28 healthy volunteers as a control group (19 males and
9f e m a l e s ;a g e s3 9 .7 ± 14.1years). Diabetic patients were di-
agnosed according to American Diabetes Association crite-
ria [4]. The control group was selected from subjects that
attended the outpatient Endocrine Clinic at Governador
Celso Ramos Hospital. All subjects gave written informed
consent prior to participation and the study was approved
by the Committees on Medical Ethics of both the Federal
University of Santa Catarina and Governador Celso Ramos
Hospital. The study was carried out in accordance with
the regulations and recommendations of the Declaration of
Helsinki.
The following exclusion criteria were used for all sub-
jects: acute and chronic inﬂammatory diseases, haemoglo-
binopathies, BMI above or equal to 30 and/or less than
19kg/m2, not having recently received any antibiotics or
anti-inﬂammatory drugs and no recent history of trauma. In
addition, glucose intolerance (fasting or after glucose load)
wasalsousedasacriterionforexclusioninthecontrolgroup.
After analysis of either diabetic or nondiabetic records, if
each one fulﬁlled the criteria to participate either in the con-
trol or in the diabetic group, an invitation was given by one
of the authors.
The following clinical information was obtained from
all participants: current medication consumption, presence
of macrovascular disease (prior myocardial infarction and
stroke history) and family cardiovascular disease, cigarette
consumption, and Framingham risk score [2]. All diabetic
patients had been screened for retinopathy by an experi-
ent ophthalmologist. Hypertension was deﬁned as history
of arterial hypertension with or without antihypertensive
treatment and/or > 130mm Hg systolic and/or > 80mm
Hg diastolic arterial blood pressure (mean of 3–5 repeated
blood pressure measurements). Hypercholesterolemia, hy-
pertriglyceridemia, low HDL-cholesterol, and high LDL-
cholesterol were deﬁned according to recommendations for
clinical practice [2]. BMI was calculated as an index of the
weight in kilograms divided by the square of the height in
meters.
All subjects were asked to discontinue aspirin, if they
were using it, at least two weeks prior to blood collec-
tions.
LaboratoryProcedures
All subjects were advised to take no medication on the
morning before the blood sample was collected. Initially,
fasting blood samples were taken between 8:00 and 10:00
a.m. for blood cell analysis and determination of creatinine,
HbA1c, total cholesterol, HDL-cholesterol, and triglycerides.
At this time, random (control group) or timed (24h, dia-
betic group) collection of urine to measure microalbumin-
uria was also requested. In approximately 5–10 days after,
fasting blood samples were collected for the measurement
of TNF-α,s I L - 2 R ,N O x, CRP, and erythrocyte sedimentation
rate (ESR). Serum aliquots for cytokines and NOx determi-
nations were stored at −20◦C.
Analyticaldeterminations
NOx determinations
NOx w a sm e a s u r e da si t sb r e a k d o w np r o d u c t sn i t r i t e
(NO2
−−)andnitrate(NO3
−)usingtheGriessmethod[5–7].
Onthedayoftheexperiments,sampleswerethawedtoroom
temperature and deproteinized by the addition of 6mM
sodium hydroxide and .6% of zinc sulphate. Afterwards,
250μL of sample was diluted in 30μL ammonium formate,
30μL of hydrated disodium hydrogen phosphate-12, and
30μLo fEscherichia coli (EC ATCC 25922: diluted (1:10) in
PBS, pH = 7.6), and then the mixture was incubated for 2h
at37◦C.Aftercentrifugationat50xg for5minutes,250μLof
thesupernatantwastransferredtocuvettesandthesamevol-
ume of fresh Griess reagent 5% ((vol./vol.) of hydrated dis-
odium hydrogen phosphate-12, 1% of sulphanilic acid, and
.1% of N-(1-naphthyl) ethylenediamine) was added and in-
cubated for 10minutes at room temperature. The reaction
of NO2
−− with this reagent produces a pink colour, which
was quantiﬁed by colorimetry at 543nm against standards
(0–150μM) on a spectrophotometer (Hitachi U2001, Model
121-0031, USA).
TNF-αandsIL-2Rdeterminations
On the day of the measurements, samples were thawed
to room temperature. Both TNF-α a n ds I L - 2 Rw e r em e a -
sured by enzyme-linked immunosorbent assay (Boehringer
Mannheim Biochemical, Ind, USA) methodologies. Ranges
of the values detected by these assays were TNF-α,5 –
1000pg/mL; and sIL-2R, 50–100pmol/L. The intra- and in-
terassay coeﬃcients of variation were 4.6–6.7% and 6.3–
5.3%, respectively, sensitivities of 1.2 and 20.0pg/mL. The
principle of these tests is based on the two-step sandwich
technique. Brieﬂy, sample aliquots and standards (20μL) of
each assay were transferred to the wells of a microtitre plate
and incubated at room temperature (4h). Then, the sam-
ples were washed three times with washing solution (compo-
sition: NaCl, 137mM; KCl, 2mM; and phosphate, 10mM;
pH7.6), followed by the addition of 200μLo fs u b s t r a t e
solution to the wells. The microtitre plate was then pro-
tected from light and maintained at room temperature (20–
30min). The reaction was stopped by adding 50μLo fs u l -
phuricacid(1mol/L).Oneminutelater,theconcentrationof
cytokines in each well was determined (Organon, NJ, USA).
When indicated by the manufacturer, the procedures were
carried out on a shaker (250r.p.m.).
Otherlaboratoryanalysis
HbA1c was determined by high performance liquid chro-
matography (HPLC, Variant II, Bio Rad, USA, reference
range up to 6%). CRP was determined by a latex enhanced
assay using the BN II apparatus (Dade Behring, Germany,
reference range up to 3mg/L). Microalbuminuria was mea-
sured by nephelometry (Dade Behring, Germany, reference
range up to .03mg/mg creatinine for random specimensFl´ avia Ozorio Pereira et al 3
Table 1: Clinical and laboratory characteristics of the studied groups. n =number of subjects, F =female, M =male, Y/N =yes/no, NS =
not signiﬁcant, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, ESR =, erythrocyte sedimentation
rate ∗∗ = P<. 01, §=mean ± SD, §§ = median (with the 25th and 75th centiles-quartiles), P values obtained from either unpaired
Student t test, λ2 test, or Mann-Whitney U test.
Characteristics Diabetic group Control group P
n 39 28 —
Sex (M/F) 18/21 19/09 NS
Age (years) § 53.3 ±93 9 .7 ±14.1 ∗∗
BMI (kg/m2) § 26.8 ±2.62 4 .7 ±3.2 ∗∗
Cigarette smoking (Y/N) 3/36 3/25 NS
SBP (mm Hg) § 132.9 ±17.2 119.6 ±16.2 ∗∗
DBP (mm Hg) § 81.6 ±8.57 7 .1 ±13.6N S
Hematocrit (%) §§ 42.2 (40.2 −44.3) 40.3 (38.6 −45.2) NS
Creatinine (mg/dL) § .84 ±.2 .8 ±.2N S
ESR (mm/h) § 11.4 ±51 0 .8 ±5.8N S
HbA1c (%) §§ 7.0 (6.0 −8) 5.4 (4.9 −5.6) ∗∗
and up to 30mg/24h volume) [8]. Total cholesterol, HDL-
cholesterol, and triglycerides were measured with standard
assays in an ADVIA 1650 apparatus (Bayer, USA). LDL-
cholesterol was estimated according to the Friedwald for-
mula. The reference values for the lipid proﬁle were accord-
ing to established guidelines [2].
Statisticalanalysis
Data are presented as mean ± SD if normally distributed
and as median (with the 25th and 75th centiles-quartiles)
if not normally distributed (HbA1c, hematocrit, microalbu-
minuria, CRP, NOx,a n dT N F - α levels). To determine diﬀer-
ences between groups, either parametric student’s t tests or
Mann-Whitney U tests were used. λ2 test was used to eval-
uate diﬀerences in proportions. Correlations were expressed
as Spearman’s correlation coeﬃcients. The level of statistical
signiﬁcance was set at P<. 05.
Results
The baseline characteristics of the studied participants are
presented in Table 1. The groups did not diﬀer in relation to
sex, smoking, and nutritional status as indirectly evaluated
by creatinine and blood (red and white) cell analysis. Neither
group presented clinical or laboratorial (ESR and CRP val-
ues) evidence of either acute or chronic inﬂammatory dis-
eases, except for one diabetic patient whose CRP level was
greater than 10mg/L and who consequently was excluded
from analyses.
Diabetic patients were overweight (mean BMI values =
26.8 ± 2.6kg/m 2), whereas the control group presented nor-
mal values (mean BMI = 24.7 ± 3.2kg/m 2)( P<. 01). Inas-
much, HbA1c levels in diabetic patients were higher than
those in the control group (P<. 01).
Othercharacteristicsofthediabeticgrouparedepictedin
Table 2. Eight (20.5%) patients had microalbuminuria, while
26 (66.6%) had hypertension. Microvascular complications
were detected in 39% but clinical evidence of macrovascu-
lar disease was observed in only 12.1%. All patients received
treatment for DM, the majority of them were on monother-
apy (71.8%) (Table 2).
In the control group, three subjects had hypertension
but only two were receiving treatment. Microalbuminuria
values in random samples were normal (median total pro-
tein/creatinine ratio: .01mg/mg of creatinine, 25th and 75th
centiles-quartiles = .004 and .02mg/mg).
As shown in Table 3, the median values of TNF-α,s I L -
2R, NOx, and mean triglyceride concentrations were higher
in the diabetic group in comparison to those obtained in
the control group (P<. 05). The other variables (HDL-
cholesterol, total cholesterol, and LDL-cholesterol) did not
diﬀer between the groups. Furthermore, median values of
CRP also did not diﬀer among diabetic and control groups
(Table 3). Individual values of CRP were distributed as low
(< 1 ) ,m o d e r a t e( 1t o3 ) ,a n dh i g h( > 3mg/L) according to
Ridker PM [9]. According to this classiﬁcation, there were no
diﬀerences within the same subgroup among control and di-
abetic subjects. However, some subjects of the control group
as well as some diabetic patients presented CRP levels higher
than 3mg/L (Figure 1).
Determinations of 10-year risk of coronary event were
done by using Framingham risk score [2]. As expected, only
diabetic persons had the high-risk scores (class 1), whereas
subjects from control groups were classiﬁed among sub-
groups 2 and 3. In agreement with Framingham risk score,
higher increase of CRP levels was observed in class 2 than in
class 3 (Figure 2)( P<. 05).
In the diabetic group, a positive association was found
amongCRPlevelsandtriglyceridesconcentrations(r = .45),
whereasanegativeassociationwasobservedamongNOx val-
ues and TNF-α determinations (r =− .3) (Figures 3(a) and
3(b)). No signiﬁcant association was found among the stud-
ied variables in the control group.
Diabetic women (n = 21) presented higher levels of
TNF-α (median; 25th and 75th centiles-quartiles = 190;4 Mediators of Inﬂammation
Table 2: Baseline clinical characteristics of studied diabetic patients. n = number of subjects, §=mean and range, §§ = median
(with the 25th and 75th centiles-quartiles), ∗=number of cases. †=treated with metformin, sulphonylurea, or insulin. †† =
treated with two or more agents.
n 39
Time of disease (years) § 7.1 (1 −17)
Microalbuminuria (mg/24h) §§ 10 (6.9 −36.9) (8/39)∗
Microvascular complications 15/39
Macrovascular complications (clinical evidence) 5/39
Diabetes treatment 39/39
Monotherapy† 28/39
Therapy combination†† 11/39
Lipid treatment 9/39
Hypertension treatment 26/39
Table 3: Serum concentrations of the studied parameters. n = number of subjects, TNF-α = tumour necrosis factor alpha, sIL-2R =
soluble interleukin 2 receptor, NO
x = nitric oxide metabolites, §=median (with the 25th and 75th centiles-quartiles), §§ = mean ± SD,
NS = not signiﬁcant, ∗=P<. 05, ∗∗ = P<. 01, ∗∗∗=P<. 001.
Parameters Diabetic patients Control group P
n 39 28 —
CRP (mg/L) § 1.4 (.7 −2.7) 2.0 (.5 −4.3) NS
TNF-α (pg/mL) § 100 (39 −235) 12 (6 −26.5) ∗∗∗
sIL-2R (pmol/mL) § 89.4 (74.3 −112.8) 74.7 (56.0 −106.0) ∗
NOx (μmol/L) § 8.34 (6.3 −15.2) 6.8 (5.1 −9.3) ∗
HDL-cholesterol (mg/dL) §§ 51.2 ±13.45 6 .6 ±14 NS
LDL-cholesterol (mg/dL) §§ 128.7 ±36.8 122.6 ±38.7N S
Total cholesterol (mg/dL) §§ 208.5 ±44.5 199 ±40.8N S
Triglycerides (mg/dL) §§ 148.5 ±59.79 2 .9 ±43.4 ∗∗
91–380pg/mL), total cholesterol (mean ± SD = 223 ±
49.5mg/dL), LDL-cholesterol (mean ± SD = 140 ± 38.9
mg/dL), and HDL-cholesterol (mean ± SD = 55.8 ±
14.8mg/dL) in comparison to diabetic men (n = 18,
TNF-α = 70; 28–105pg/mL, total cholesterol = 191.8 ±
31.4mg/dL, LDL-cholesterol = 117.8 ± 28.1mg/dL, and
HDL-cholesterol = 45.7 ± 9mg/dL). On the other hand, no
diﬀerences among sexes were observed in the control group.
DISCUSSION
The data from this study demonstrate that TNF-α,s I L - 2 R ,
NOx, and triglycerides, but not CRP, are increased in this
subgroup of diabetic patients. These results conﬁrm reports
in the literature that a low-grade inﬂammation exists in type
2 diabetic patients in spite of the absence of obesity and sig-
niﬁcant hyperglycaemia. In addition, these results also show
that in the diabetic group, the inﬂammatory markers signiﬁ-
cantlydiﬀeramongthesexes,beinghigherinwomenincom-
parison to men.
A relationship between TNF-α and diabetes has been de-
scribed in several stages of this disease. Thus, increased TNF-
α levels have been associated with (1) other cytokines and in-
creased risk of developing diabetes [9]; (2) high triglycerides
concentrations in metabolic syndrome [10]; and (3) a sig-
niﬁcant number of both fatal and nonfatal cardiovascular
outcomes [11]. In this study, diabetic patients presented el-
evated levels of TNF-α in spite of being nonobese, but over-
weight and with median levels of HbA1c of 7% (maximum
of 8%). In addition, raised serum levels of NOx and sIL-
2R also were detected in this group. It is reported that in-
creased serum levels of NOx indirectly reﬂect the presence
of either endothelial dysfunction or vascular injury, includ-
ing microvascular complications [12, 13]. Several hypothe-
ses have been raised to explain the increased serum levels of
NOx indiabeticpatients.Chiarellietal[14]reportedthatthe
HbA1c concentration was signiﬁcantly and positively related
to NO2
−− plus NO3
− serum content, whereas others have
suggested that the raised levels of NOx could reﬂect the neg-
ative feedback with cyclic guanosine-3 ,5  -monophosphate
(cGMP) [15] since NOx interacts with soluble guanylate cy-
clase, leading to elevation of cGMP concentrations. In this
instance, vasodilation would be blunted in diabetic subjects,
not because of an inability to produce NOx, but rather due
to an inhibition of the action of NOx presumably secondary
to the generation of cGMP which is reported to be low [16].
One cannot discard, however, the possibility that besides the
hypothesis of the existence of a defect in the generation ofFl´ avia Ozorio Pereira et al 5
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Figure 1: Distribution of CRP in diabetic () and control ()
groups. Data are shown using three simple clinical cut-oﬀ points
for CRP: less than 1, 1 to 3, and greater than 3mg/L.
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Figure 2: Distribution of CRP levels and Framingham risk scores
(1, 2, and 3) in diabetic (D) and control (C) groups. The solid lines
represent the median values of each subgroup; ∗=P<. 05.
cGMP, other sources of NOx could be contributing to its
serum level via the expression of induced NO-synthase by
inﬂammatory cells (macrophages, neutrophils, and vascular
muscle cells, among others). Furthermore, the ﬁndings of
raised levels of sIL-2R in diabetic patients are in accordance
with those reported by Doganay et al [17] and this indi-
cates activation of T lymphocytes [18]. Taken together, these
ﬁndings suggest that this group of diabetic patients present
a low-grade inﬂammation triggered by the diabetic melli-
tus state, which is favouring the progression of accelerated
atherosclerosis. Within this context, data from the UKPDS
havedemonstratedthatabout50%ofnewlydiagnosedtype2
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Figure 3: (a) Correlation between the concentrations of CRP and
triglycerides in diabetic patients; r = .45 and p<. 01. (b) Correla-
tion between the concentrations of TNF-α and NOx in the diabetic
patients; r =− .3a n dp<. 05. Each individual value is represented
by a symbol (). r = Spearman’s rank correlation coeﬃcients.
DM present some evidence of cardiovascular complications,
[1] conﬁrming data shown by others [16, 19, 20] that the in-
ﬂammation course of the atherosclerotic process is more se-
vere in diabetic patients than in nondiabetic subjects. How-
ever, in contrast to other clinical studies [21, 22], we do not
have a clear explanation of the negative relationship between
the serum concentrations of TNF-α and NOx.
Inagreementwithotherstudies[23,24],ourstudyfound
that CRP is not a surrogate marker for cardiovascular disease
indiabeticpatients,unlesseitherkidneydysfunctionorpoly-
morphisms in loci for CRP are present [25]. However, fur-
ther studies are needed to better evaluate the outcome of
the diabetic subgroup that presented high levels of CRP. Re-
cently, Schulze et al [26] reported that high plasma levels
of CRP were associated with an increased risk of cardiovas-
cular events among diabetic men, independent of currently
established lifestyle risk factors, blood lipids, and glycaemic
control. Regarding the present study, one cannot rule out
the possibility that the absence of obesity, signiﬁcant hy-
perglycaemia, and the normal levels of HDL-cholesterol in6 Mediators of Inﬂammation
the diabetic group may have contributed to these results.
In addition, the ﬁnding that serum levels of both CRP and
triglycerides are positively correlated provides a further in-
dication that both variables contribute to the vascular in-
ﬂammatory process. On the other hand, as it was previ-
ously demonstrated, individual analysis of CRP showed that
its high levels are related with increased Framingham risk
score and is useful in identifying nondiabetic individuals
whoshouldbeconsideredformoreprotectivetreatmentpro-
grams [27, 28].
A signiﬁcant ﬁnding in the present study was the results
in the subgroup of diabetic women. Considering that once
cardiovasculardiseaseispresentinwomen,theyhaveaworse
outcome than male counterparts, the same statement is valid
for diabetic women [29, 30]. An elevated cardiovascular risk
has been recognized in this subgroup in comparison to dia-
beticmen,evenintheabsenceofhypertension,dyslipidemia,
and before the menopause [31, 32]. In agreement with these
data, the present work found high serum levels of TNF-α,
total cholesterol, and LDL-cholesterol in diabetic women in
comparison to diabetic men.
In conclusion, our study shows that some surrogate
markers of cardiovascular inﬂammation are elevated in dia-
beticpatients.Takentogether,thesedatasupporttheopinion
that diabetic patients present a high risk for cardiovascular
disease and need early aggressive intervention.
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